Even in Denmark — Novo Nordisk's house industry — an application for Wegovy to get general public wellness insurance policy coverage was rejected around the grounds that its cost was incommensurate with its therapeutic value.Meantime, offer constraints could dampen Original distribution in a industry forecast to become worthy of $two hundred bi